Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease

NCT01925001 is registered in ClinicalTrials.gov with Sangart as lead sponsor.

NCT NCT01925001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01925001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease
Lead sponsor
Sangart
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 2013
Completion date
October 31, 2015
Enrollment
0 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, sickle cell, hemoglobin sc disease, sickle cell anemia, sickle cell disease, sickle cell disorders, sickle cell hemoglobin c disease